

Q-MIND

For the use of a Psychiatrist only

Abbreviated Prescribing information for Q-MIND Tablets (Quetiapine fumarate Tablets)
[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES: Quetiapine fumarate is an anti-psychotic drug belongs to dibenzothiazepine derivative. It shows the pharmacological action by inhibiting dopamine type 2 (D₂) and serotonin type 2 (5HT₂).

INDICATIONS: It is used in treatment of Schizophrenia.

DOSAGE AND ADMINISTRATION: Quetiapine can be taken with or without food. Recommended dose *for adults:* 150-750 mg/day, *for adolescents:* 400-800 mg/day, *maintenance dose:* 400– 800 mg/day.

CONTRAINDICATIONS: In patients with known hypersensitivity to this medication or any of its ingredients.

WARNINGS & PRECAUTIONS: Increased mortality in elderly patients with dementia-related psychosis, patients with major depressive disorder may experience worsening of their depression and/or the emergence of suicidal ideation and behavior or unusual changes in behavior. Cerebrovascular Adverse Reactions and Neuroleptic Malignant Syndrome (NMS) may occur with quetiapine. Metabolic changes, irreversible, involuntary, dyskinetic movements and may develop with quetiapine, hypotension, increases in blood pressure (children and adolescents), leukopenia, neutropenia, agranulocytosis, cataracts, QT prolongation, seizures, hypothyroidism, Hyperprolactinemia, potential for cognitive and motor impairment, dysphagia and acute withdrawal symptoms, such as insomnia, nausea, and vomiting have been described after abrupt cessation of quetiapine.

DRUG INTERACTIONS: Caution should be used while taking in other centrally acting drugs, the cognitive and motor effects of alcohol potentiated while taking quetiapine, CYP3A4 inhibitors increases quetiapine's pharmacological effect while CYP3A4 inducers decreases. It may enhance the effects of antihypertensive agents and may antagonize the effects of levodopa and dopamine agonists.

ADVERSE REACTIONS: Cerebrovascular adverse reactions, stroke, flu syndrome, anorexia, vasodilatation, QT interval prolonged, migraine, bradycardia, cerebral ischemia, irregular pulse, T wave abnormality, bundle branch block, cerebrovascular accident, deep thrombophlebitis, T wave inversion, flu syndrome, anorexia, cough increased, dyspnea, transaminase elevations, anaphylactic reaction, cardiomyopathy, hyponatremia, myocarditis, nocturnal enuresis, pancreatitis, retrograde amnesia, rhabdomyolysis, syndrome of inappropriate antidiuretic hormone secretion (SIADH), Stevens-Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN) etc.

MARKETED BY:



TORRENT PHARMACEUTICALS LTD.

Torrent House, Off Ashram Road,
Ahmedabad-380 009, INDIA

IN/Q-MIND/FEB 2015/01/AbPI

(Additional information is available on request)